Madison, WI (PRWEB) April 19, 2013
BellBrook Labs' Transcreener® HTS Assay products will be available exclusively from Cambio in the UK as of April 2013. The two companies initiated their business alliance in April of 2012, and Cambio’s rapid success in penetrating UK drug discovery laboratories with the Transcreener ADP Assay and related products prompted BellBrook to grant them exclusive distribution rights for the Transcreener products for the first time in a European country.
The revised agreement includes the full Transcreener® product line of HTS assays covering thousands of enzymes, including established target families like kinases as well as emerging target families such as methyltransferases, GTPases, and glycosyltransferases. Transcreener assays are the only method for direct detection of nucleotide enzyme products, which provides significant advantages over other HTS enzyme assay methods in terms of sensitivity, signal stability and resistance to interference. They are designed for an automated HTS environment with single addition, mix-and-read format and overnight reagent and signal stability and are available in three different fluorescent readouts; FI, FP and TR-FRET.
Cambio will also distribute BellBrook’s new Transzyme™ product line of turn-key methyltransferase assay kits that combine pre-calibrated purified methyltransferase enzymes and substrates from Reaction Biology with BellBrook’s Transcreener EPIGEN Methyltransferase detection reagents. The Transzyme kits allow investigators to start screening or profiling methyltransferases without the costly reagent testing and assay development normally associated with these complex enzyme systems.
About BellBrook Labs. BellBrook Labs is dedicated to accelerating drug discovery and biological research by providing innovative high throughput screening solutions for enzymes and phenotypic assays. The company’s Transcreener® HTS enzyme assays, used by all of the major pharmaceutical companies, make it easy to screen thousands of different enzymes, including validated targets like kinases, as well as emerging targets like ATPases, GTPases, methyltransferases, and glycosyltransferases. The iuvo™ Microconduit Array technology and assay screening service is a line of unique microscale devices for miniaturization and automation of advanced cell models that are more representative of human physiology. Visit BellBrook’s website for more information: http://www.bellbrooklabs.com.
About Cambio. Established in 1985, Cambio is a privately-held UK company with an excellent reputation for the supply of high quality molecular biology reagents and consumables. To meet the needs of a growing and diversifying market, advanced Molecular Biology products are continually added to the company’s extensive portfolio. This wide choice of research tools sourced from a global network of leading manufacturers is complemented by Cambio’s commitment to world-class technical support and customer service. As a result, the company has built successful long-term customer relationships with scientific research laboratories within universities, large pharma and biotech companies, government agencies, agricultural organisations and environmental facilities. Based near Cambridge, UK, Cambio is ISO9001:2008 registered. http://www.cambio.co.uk/
Read the full story at http://www.prweb.com/releases/2013/4/prweb10643831.htm.
Copyright©2012 Vocus, Inc.
All rights reserved